Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma

Expert Opinion on Drug Delivery

Volumn 5, Issue 1, 2008, Pages 137-145

  Kalsi, Jas ^a   Harland, Stephen J ^b   Feneley, Mark R ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chemotherapy; Electromotive drug administration; Intravesical; Mitomycin C; Non invasive bladder cancer; Transitional cell carcinoma

Indexed keywords

BCG VACCINE; LIDOCAINE; MITOMYCIN C;

BLADDER CARCINOMA; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYSTECTOMY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; ELECTROMOTIVE DRUG ADMINISTRATION; ELECTROOSMOSIS; FEASIBILITY STUDY; HUMAN; HYPERTHERMIA; INVASIVE CARCINOMA; IONTOPHORESIS; LEUKOPENIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; REVIEW; SKIN MANIFESTATION; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; HUMANS; IONTOPHORESIS; MITOMYCIN; NEOPLASM INVASIVENESS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 39049143756     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.1.137     Document Type: Review

References (47)

1. Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003;170(3):777-82
2. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006;7(1):43-51
3. Riedl CR, Knoll M, Plas E, Pfluger H. Intravesical electromotive drug administration technique: preliminary results and side effects. J Urol 1998;159(6):1851-6
4. Lugnani F, Mazza G, Cerulli N, Rossi C, Stephen R. Iontophoresis of drugs in the bladder wall: equipment and preliminary studies. Artif Organs 1993;17(1):8-17
5. Fontanella UA, Rossi CA, Stephen RL. Bladder and urethral anaesthesia with electromotive drug administration (EMDA): a technique for invasive endoscopic procedures. Br J Urol 1997;79(3):414-20
6. Dasgupta P, Fowler CJ, Stephen RL. Electromotive drug administration of lidocaine to anesthetize the bladder before intravesical capsaicin. J Urol 1998;159(6):1857-61
7. Jewett MA, Valiquette L, Sampson HA, Katz J, Fradet Y, Redelmeier DA. Electromotive drug administration of lidocaine as an alternative anesthesia for transurethral surgery. J Urol 1999;161(2):482-5
8. Fontanella UA, Rossi CA, Stephen RL. Iontophoretic local anaesthesia for bladder dilatation in the treatment of interstitial cystitis. Br J Urol 1992;69(6):662-3
9. Gurpinar T, Wong HY, Griffith DP. Electromotive administration of intravesical lidocaine in patients with interstitial cystitis. J Endourol 1996;10(5):443-7
10. Rosamilia A, Dwyer PL, Gibson J. Electromotive drug administration of lidocaine and dexamethasone followed by cystodistension in women with interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct 1997;8(3):142-5
11. Riedl CR, Knoll M, Plas E, Pfluger H. Electromotive drug administration and hydrodistention for the treatment of interstitial cystitis. J Endourol 1998;12(3):269-72
12. Di Stasi SM, Giannantoni A, Vespasiani G, et al. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens. J Urol 2001;165(2):491-8
13. Riedl CR, Stephen RL, Daha LK, Knoll M, Plas E, Pfluger H. Electromotive administration of intravesical bethanechol and the clinical impact on acontractile detrusor management: introduction of a new test. J Urol 2000;164(6):2108-11
14. Montorsi F, Salonia A, Guazzoni G, et al. Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results. J Androl 2000;21(1):85-90
15. Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial. J Urol 2007;177(3):972-5
16. Di Stasi SM, Giannantoni A, Stephen RL, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 2004;171(4):1605-8
17. Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996;156(6):1934-41
18. Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993;149(4):749-52
19. Sylvester RJ, Oosterlinck W, Van Der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171(6 Pt 1):2186-90, quiz
20. Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996;155(4):1233-8
21. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999;161(4):1120-3
22. Cliff AM, Romaniuk CS, Parr NJ. Perivesical inflammation after early mitomycin C instillation. BJU Int 2000;85(4):556-7
23. Oehlschlager S, Loessnitzer A, Froehner M, Hakenberg OW, Manseck A, Wirth MP. Distal ureteral stenosis after early adjuvant intravesical mitomycin C application for superficial bladder cancer. Urol Int 2003;70(1):74-6
24. Racioppi M, Porreca A, Foschi N, Delicato G, Destito A, D'Addessi A. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C. Urol Int 2005;75(4):373-5
25. Wajsman Z, McGill W, Englander L, Huben RP, Pontes JE. Severely contracted bladder following intravesical mitomycin C therapy. J Urol 1983;130(2):340-1
26. Oddens JR, Van Der Meijden AP, Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur Urol 2004;46(3):336-8
27. Kaasinen E, Rintala E, Hellstrom P, et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002;42(2):167-74
28. Sylvester RJ, Van Der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168(5):1964-70
29. Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63(4):682-6
30. Van Der Meijden AP, Sylvester R, Oosterlinck W, et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 2005;48(3):363-71
31. Oosterlinck W. Guidelines on diagnosis and treatment of superficial bladder cancer. Minerva Urol Nefrol 2004;56(1):65-72
32. Sylvester RJ, Van Der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3):466-5
33. Wientjes MG, Badalament RA, Wang RC, Hassan F, Au JL. Penetration of mitomycin C in human bladder. Cancer Res 1993;53(14):3314-20
34. Dalton JT, Wientjes MG, Badalament RA, Drago JR, Au JL. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 1991;51(19):5144-52
35. Wientjes MG, Badalament RA, Au JL. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol 1993;32(4):255-62
36. Gao X, Au JL, Badalament RA, Wientjes MG. Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Clin Cancer Res 1998;4(1):139-43
37. Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized Phase III trial. J Natl Cancer Inst 2001;93(8):597-604
38. Di Stasi SM, Giannantoni A, Massoud R, et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res 1999;59(19):4912-18
39. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 1997;89(7):480-7
40. Brausi M, Campo B, Pizzocaro G, et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Urology 1998;51(3):506-9
41. Rintala E, Jauhiainen K, Rajala P, Ruutu M, Kaasinen K, Alfthan O. Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. J Urol 1995;154(6):2050-3
42. Rintala E, Jauhiainen K, Kaasinen E, Nurmi M, Alfthan O. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group. J Urol 1996;156(1):56-9
43. Witjes JA, Meijden AP, Sylvester LC, Debruyne FM, van Aubel A, Witjes WP. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 1998;52(3):403-10
44. Kaasinen E, Wijkstrom H, Malmstrom PU, et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol 2003;43(6):637-45
45. Gofrit ON, Shapiro A, Pode D, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 2004;63(3):466-71
46. van der Heijden AG, Kiemeney LA, Gofrit ON, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004;46(1):65-71
47. Colombo R, Brausi M, Da Pozzo L, et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication, a pilot study on marker lesion. Eur Urol 2001;39(1):95-100